Theravance Biopharma, Inc.
TBPH
$14.30
$0.130.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.20M | 15.39M | 18.75M | 16.87M | 14.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.20M | 15.39M | 18.75M | 16.87M | 14.26M |
| Cost of Revenue | 10.49M | 11.45M | 9.45M | 9.27M | 9.95M |
| Gross Profit | 15.71M | 3.94M | 9.30M | 7.60M | 4.30M |
| SG&A Expenses | 18.43M | 18.37M | 18.50M | 16.88M | 17.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.92M | 29.82M | 27.95M | 26.14M | 27.01M |
| Operating Income | -2.73M | -14.43M | -9.20M | -9.28M | -12.75M |
| Income Before Tax | 73.21M | -14.14M | -8.94M | -10.05M | -15.22M |
| Income Tax Expenses | 18.37M | -559.00K | 6.59M | 2.65M | 1.31M |
| Earnings from Continuing Operations | 54.84M | -13.58M | -15.53M | -12.70M | -16.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.84M | -13.58M | -15.53M | -12.70M | -16.53M |
| EBIT | -2.73M | -14.43M | -9.20M | -9.28M | -12.75M |
| EBITDA | -2.32M | -14.02M | -8.78M | -8.85M | -12.33M |
| EPS Basic | 1.09 | -0.27 | -0.31 | -0.26 | -0.34 |
| Normalized Basic EPS | 0.91 | -0.18 | -0.11 | -0.11 | -0.16 |
| EPS Diluted | 1.08 | -0.27 | -0.31 | -0.26 | -0.34 |
| Normalized Diluted EPS | 0.90 | -0.18 | -0.11 | -0.11 | -0.16 |
| Average Basic Shares Outstanding | 50.18M | 49.71M | 49.31M | 49.04M | 48.75M |
| Average Diluted Shares Outstanding | 50.73M | 49.71M | 49.31M | 49.04M | 48.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |